Maryland Families for Stem Cell Research is a organization of individuals with personal connections to disease and injuries, former elected officials, doctors, scientists, bioethics experts, biotech industry leaders, and health care professionals working together to educate citizens about biomedical research and regenerative medicine. Join our effort and help us find cures.
http://www.stemcellresearchreport.com
The Stem Cell Research Report provides quick, useful information for those who are decision and policy makers in the area of stem cell research. The Report will keep you current on the research, studies and treatment worldwide. Looking for good information for your educational and lobbying efforts? Then you need to subscribe.
Ex Vivo Technologies is a privately held biotechnology company focusing on the engineering of adult-derived stem cells for cellular therapeutics. By controlling the cells telomere biology, Ex Vivo has demonstrated the ability to exponentially increase the proliferation potential of the adult-derived stem cell while controlling differentiation and the cells genomic stability. Using this technology, Ex Vivo will initially target autologous cellular therapies where obtaining adequate numbers of cells is a critical limitation in their use.
http://www.thebradykohnfoundation.org
Founded in 2002, the Brady Kohn Foundation, Inc. is a tax-exempt not-for-profit organization, created by Carolyn and Andrew Kohn, in loving memory and in honor of their son, Andrew "Brady" Kohn with the huge support of family and friends. This volunteer-driven organization welcomes your participation.
HistoGenetics provides a suite of tissue-typing services with the highest level of quality assurance and accelerated turnaround time for results. With around-the-clock operations and redundancies built in to our processes, we can meet tight deadlines for typing requests without sacrificing accuracy. We process all samples and typing requests with state-of- the art automated instrumentation and bioinformatics tools. Accuracy of allele level typing is further assured by built-in redundancies. Routine results are available at client specified deadlines between seven and fourteen days. HistoGenetics can provide results in two to three days if required.
http://www.primecelltherapeutics.com
PrimeCell(TM) Therapeutics LLC, a PrimeGen Biotech company, is devoted exclusively to germ line stem cell reprogramming. Its next generation stem cell - PrimeCell(TM) - is an adult stem cell derived from the germ line and reprogrammed to exhibit pluripotency. Its innovative science and unique approach qualify PrimeCell Therapeutics as one of the preeminent biotechnology firms within the emerging field of regenerative medicine.
Angioblast Systems, Inc. ("Angioblast" or the "Company") is a privately held biotechnology company formed in 2001. The Company is committed to becoming a world leader in the development and commercialization of novel therapeutic products for the treatment of cardiovascular diseases ("CVD"). Angioblast intends to achieve this goal through the advancement of its three lead and groundbreaking product candidates that have each been proven to be effective in animal models of human CVD: special adult stem cells called Mesenchymal Precursor Cells ("MPC") peptide-based therapeutics that induce stem cell migration, angiogenesis, and cardiovascular recovery, the lead candidate being stromal-derived factor 1 ("SDF-1") products delivered in drug-eluting stents for coronary and peripheral artery disease, consisting of RNA silencing technology, the lead candidate targeting the blood vessel and clotting regulator plasminogen activator inhibitor type I ("PAI-1") Each of the Company's lead products and underlying proprietary technology platforms (which are covered by an extensive patent portfolio) operates primarily by regulating blood vessel growth. Therefore, these lead product candidates and the related technologies are applicable to a broad range of diseases where new blood vessel growth may be useful, including congestive heart failure, myocardial infarction (heart attack), peripheral arterial disease and skin ulcers. The Company's most advanced product is the MPC therapy, which has achieved outstanding results in extensive pre-clinical development in animal models of several cardiovascular diseases, including studies focused on the regeneration and repair of heart muscle and growth of new blood vessels following a heart attack injury. This product represents what Angioblast believes is the world's leading adult stem cell technology, a groundbreaking advancement in stem cell-based clinical treatment, and which is currently being evaluated in a human clinical trials for treatment of heart damage following a heart attack. The competitive advantages of MPC that make this a unique and highly valuable product are : Characteristic
http://www.stemcellauthority.com
Welcome to Stem Cell Authority, Ltd. - a national company dedicated to providing physicians who deliver babies with the most comprehensive state-of-the-art stem cell banking program available today, which allows their maternity patients to take advantage of today's advances in stem cell technology. Stem Cell Authority Ltd.'s business method is proprietary and a patent is pending. Our stem cell banking program is unique in the industry because we work directly with Physicians to facilitate the collection and banking of their maternity patients' stem cells. One of the many advantages for participating physicians includes Stem Cell Authority Ltd.'s exclusive licensing arrangement in the United States to offer parents the opportunity to bank their newborn's HUCPVCs - Human Umbilical Cord Perivascular Cells (Mesenchymal stem cells) , a special population of ethically non-controversial stem cells that are found in the tissue immediately surrounding the blood vessels of the umbilical cord, in addition to the hematopoietic stem cells from the umbilical cord blood (used to treat diseases of the blood system). In June, 2007, Stem Cell Authority Ltd. was granted the exclusive US license for the collection, cryogenic banking, sub-licensing, and pharmaceutical manufacturing of diagnostic therapeutic compounds derived from expressions of the HUCPVC stem cells from Tissue Regeneration Therapeutics (TRT), a private, Canadian-based life sciences company that exclusively licensed the technology from the University of Toronto. Stem Cell Authority Ltd. is the only company in the United States that can offer families the collection and banking of the mesenchymal stem cell technology for autologous stem cell banking. Under the terms of the agreement, Stem Cell Authority Ltd. gains US patent rights and manufacturing know-how in return for an upfront technology access fee and annual royalties. HUCPVCs are a type of stem cell , the so called "mesenchymal stromal cells" (MSC) , also called mesenchymal stem cells , that have many varied and special properties. MSCs give rise to specialized cells in the body that make the musculo-skeletal system (bone, cartilage, fibrous tissue and muscle). MSCs have also been shown to have very special immune-regulatory functions and have been used to treat immune and inflammatory diseases. HUCPVCs, extracted from umbilical cord tissue, are the richest source of MSCs ever discovered. They can rapidly provide clinically relevant doses for stem cell therapy.
Theradigm, Inc., a portfolio company of Toucan Capital Fund II, is developing cell-based therapies for treatment of the central nervous system (CNS) disorders. Two different types of cells (1) neural stem cells and (2) bone marrow stromal cells may be applied alone or in combination to constitute unique therapies. Theradigm has a substantial intellectual property base covering use of these cells in CNS applications.
CellCyte Genetics Corporation (CellCyte) is an exploration stage company engaged in the acquisition and exploration of mineral properties with a view to exploiting any mineral deposits the Company discovered. Prior to the year ended December 31, 2006, CellCyte owned a 100% beneficial interest in one mineral claim known as the CB-1 claim. On March 30, 2007, the Company completed the acquisition of CellCyte. As a result of the acquisition of CellCyte, the Company is involved in the research and development of stem cell enabling therapeutic products and medical devices for cell production. In addition, CellCyte has purchased a cell expansion technology as a complementary addition to its therapeutic portfolio. The Company's initial focus is on the development of certain therapeutic product candidates licensed from the United States Department of Veterans Affairs. (Source: 10KSB)
EndGenitor Technologies, Inc.'s strategy is to rapidly commercialize adult stem cell products for sale to researchers in industry and academia. As it grows its market presence and diversifies its product lines, EndGenitor expects to launch proprietary novel stem cell therapeutics for the treatment of debilitating chronic degenerative diseases. The company is solely focusing on commercializing cell products from adult tissues that are free from any ethical controversy.
http://www.primegenbiotech.com
PrimeGen Biotech (www.primegenbiotech.com) is dedicated to the research and therapeutic applications of adult stem cells, leading to individualized patient therapies. Entering its fifth year of operations at the pre-clinical stage of product development, the company specializes in two core technologies: germ line stem cells and therapeutic reprogramming. Pioneering work on induced pluripotent stem cells (iPS cells), positions PrimeGen as a leader in moving this breakthrough from research to therapy. Future applications of both PrimeGen core technologies will enlist a patient's own adult tissue cells to generate stem cells for regenerative and restorative medical treatments. Based in Irvine, California, PrimeGen Biotech is a privately held, Delaware limited liability company.
Plasticell is a privately held biotechnology company using novel cell culture and drug discovery platforms to produce regenerative small molecule drugs. Plasticell aims to develop drugs by elucidating the biochemical mechanisms that control the proliferation and differentiation of stem cells, the master cells responsible for tissue development and repair. Plasticell also forms alliances with industry partners to produce high value cell lines for drug discovery research and cell therapy applications.
Tasco Holdings Inc. recently purchased Bio-Matrix Scientific Group Inc. (www.BMXGonline.com), a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market. The Company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation and is building a state-of-the-art facility in San Diego, California, to cater to the growing stem cell research segment of the $75 billion biotechnology and medical device industry.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory